Multiple sclerosis: experimental models and reality by Hans Lassmann & Monika Bradl
1 3
Acta Neuropathol (2017) 133:223–244
DOI 10.1007/s00401-016-1631-4
REVIEW
Multiple sclerosis: experimental models and reality
Hans Lassmann1 · Monika Bradl1 
Received: 9 September 2016 / Revised: 5 October 2016 / Accepted: 6 October 2016 / Published online: 20 October 2016 
© The Author(s) 2016. This article is published with open access at Springerlink.com
important to select the right experimental model to answer 
specific questions in MS research.
Introduction: basic features of MS, which should 
be mirrored in experimental models
MS is a chronic inflammatory demyelinating disease of 
the central nervous system (CNS) [91]. In most patients, 
the disease starts with a phase of relapses and remissions, 
which may after 10 to 15 years convert into the progres-
sive phase. Ten to fifteen percent of the patients miss the 
relapsing phase of the disease and develop primary pro-
gressive MS [100]. Progressive MS is generally seen in 
older patients than relapsing remitting MS, suggesting that 
age-related changes of the brain play some role for the slow 
and steady increase of neurological disability in this phase 
[141]. On pathological examination, inflammation consist-
ing of T-cell and B-cell infiltrates is invariably present in the 
CNS and lesions of MS patients. This is the case not only 
in the early relapsing, but also in the progressive phase, at 
least as long as there is evidence for active demyelination 
and neurodegeneration [53]. The degree of lymphocytic 
inflammation is higher in early than in late disease stages. 
The lymphocytic inflammatory infiltrates are dominated 
by CD8+ T-cells with much lower contribution of CD4+ 
T-cells and B-cells [24, 53, 62]. Recent results of clinical 
trials show profound effects of anti-inflammatory therapies, 
which globally target T- and B-cells or B-cells alone [150, 
152], while therapies that specifically address CD4+ T-cell-
mediated inflammation show low or even no effect [145, 
161]. Whether the effect of B-cell-directed therapies is due 
to a blockade of B-cell-mediated inflammation alone, to the 
reduction of antigen presentation for T-cells or to the elimi-
nation of Epstein Barr virus infected B-cells as a driver of 
Abstract One of the most frequent statements, provided 
in different variations in the introduction of experimental 
studies on multiple sclerosis (MS), is that “Multiple scle-
rosis is a demyelinating autoimmune disease and experi-
mental autoimmune encephalomyelitis (EAE) is a suitable 
model to study its pathogenesis”. However, so far, no single 
experimental model covers the entire spectrum of the clini-
cal, pathological, or immunological features of the disease. 
Many different models are available, which proved to be 
highly useful for studying different aspects of inflamma-
tion, demyelination, remyelination, and neurodegenera-
tion in the central nervous system. However, the relevance 
of results from such models for MS pathogenesis has to 
be critically validated. Current EAE models are mainly 
based on inflammation, induced by auto-reactive CD4+ 
T-cells, and these models reflect important aspects of MS. 
However, pathological data and results from clinical trials 
in MS indicate that CD8+ T-cells and B-lymphocytes may 
play an important role in propagating inflammation and tis-
sue damage in established MS. Viral models may reflect 
key features of MS-like inflammatory demyelination, but 
are difficult to use due to their very complex pathogen-
esis, involving direct virus-induced and immune-mediated 
mechanisms. Furthermore, evidence for a role of viruses 
in MS pathogenesis is indirect and limited, and an MS-
specific virus infection has not been identified so far. Toxic 
models are highly useful to unravel mechanisms of de- and 
remyelination, but do not reflect other important aspects of 
MS pathology and pathogenesis. For all these reasons, it is 
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the chronic inflammatory process is currently unresolved 
[61]. Overall, however, the data indicate that CD8+ T-cells 
and/or B-cells may play a more prominent role in disease 
pathogenesis, when the disease is already established. This, 
however, does not exclude that CD4+ T-cells are involved 
in triggering the inflammatory cascade at disease onset, as 
suggested by recent genetic association studies [72].
The key feature distinguishing MS from other inflamma-
tory diseases of the brain is the widespread primary demy-
elination, which gives rise to large focal lesions with com-
plete myelin loss and partial sparing of axons (Fig. 1) [91]. 
This is most impressively seen in subpial demyelinated 
lesions in the cerebral cortex, which are absolutely specific 
for MS and were not seen in any other inflammatory condi-
tion of the brain [45, 113] (Fig. 1). In addition to demyeli-
nation, there is a partial and variable degeneration and loss 
of axons in the lesions [44, 81]. However, axonal degen-
eration, nerve cell loss, and dendritic/synaptic injury also 
occur in many other inflammatory conditions in the brain 
in the absence of primary demyelination and are, thus, not 
an MS-specific pathological feature. Active demyelination 
and neurodegeneration are associated with profound micro-
glia activation and the presence of macrophage-like cells 
[45, 163]. In active lesions, astrocytes are activated and 
seem to be involved in the propagation of the inflamma-
tory response and tissue injury [26]. In established chronic 
lesions, astrocytes form a dense glial scar.
Inflammation, primary demyelination, and neurodegen-
eration are the dominant features of both, relapsing and 
progressive MS (Fig. 1). So far, no qualitative difference 
in the pathology between these different disease stages has 
been unequivocally documented. However, the abundance 
of specific features differs quantitatively [57] and makes 
the following pathological alterations the most prominent 
features of progressive MS:
1. Slow expansion of pre-existing demyelinated lesions, 
while the formation of new white matter plaques with 
massive inflammation and blood brain barrier damage 
is sparse [52].
2. Progression of axonal degeneration in the plaques and 
in the normal appearing white matter, the latter in part 
due to retrograde and anterograde neuronal degenera-
tion and in part related to inflammation in the menin-
ges and the tissue [57]. This is seen in addition to the 
acute axonal injury in active MS lesions [53].
3. Presence of cortical (subpial) demyelinated lesions 
which are very prominent and may affect up to 90 % of 
the cortical ribbon [86] (Fig. 1).
4. Occurrence of all these changes on the background of 
a moderate lymphocytic inflammatory reaction associ-
ated with profound microglia activation in the lesions 
and the adjacent white matter [53].
Is MS pathology reproduced in conditions 
of autoimmune encephalomyelitis in humans?
Before any experimental animal model of autoimmune 
encephalomyelitis has been developed, it was already clear 
that sensitization of humans with brain tissue or brain cells 
can be followed by neuroparalytic complications. This was 
seen as a side effect of anti-rabies vaccination using inac-
tivated viruses insufficiently purified from brain cells or 
brain tissues which they have been propagated in. A large 
meta-analysis of data from 150,000 vaccinated individu-
als published between 1880 and 1928 revealed that neuro-
paralytic complications occurred in an incidence of about 1 
out of 1000, and that affected patients most frequently pre-
sented with a clinical disease of acute polyradiculoneuritis 
or acute disseminated encephalomyelitis (ADEM; [157]). 
Only few of these patients developed a condition pathologi-
cally resembling MS [146, 160] (Fig. 1). We recently had 
the chance to study a similar case and found a pathological 
picture, which reflected all changes also seen in acute MS 
[64] (Fig. 1). The inflammatory infiltrates mainly consisted 
of B-lymphocytes and lower numbers of CD8+ T-cells 
and plasma cells, while CD4+ lymphocytes were virtually 
absent. These data clearly show that an MS-like disease can 
be induced by auto-sensitization with brain tissue, but there 
is a fundamental difference to MS. In all patients, disease 
subsided after the active sensitization process was stopped 
and there was no single patient, who developed chronic 
MS [157]. Similarly, in animal studies, it has been shown 
that the acute or chronic inflammatory demyelinating dis-
ease burns out when the peripheral brain antigen depot at 
the sensitization site has been removed [159]. This suggests 
that the propagation of chronic (autoimmune?) disease in 
MS requires stimulation by a persistent trigger within or 
outside the CNS.
Models of experimental autoimmune encephalomyelitis
Based on the observation of an inflammatory, in part MS-
like disease, after auto-sensitization in humans, attempts 
have been made to reproduce this disease in animal mod-
els [11, 135]. In the early phases of this research, immu-
nization was performed with emulsions of brain tissue 
dissolved in saline. This resulted in a similar disease as 
described before in humans, albeit only in a fraction of the 
sensitized animals and after multiple vaccinations over a 
long time period. To improve reproducibility, strong adju-
vants have been introduced into the sensitization protocol, 
in most cases complete Freund’s adjuvant, which pro-
vides a slow liberation of the sensitizing antigen from the 
inoculum and uses inactivated mycobacteria as a massive 
immune stimulant [75]. One effect of this adjuvant is that 
it massively stimulates phagocytic uptake and presentation 
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Fig. 1  Distribution of demy-
elinating lesions in MS and 
different EAE-based models. 
The sites of demyelinated 
lesions were shown in camera 
lucida drawings of human brain 
sections, were projected into 
schemes redrawn after Paxinos 
and Watson [124] for rat and 
murine brain sections, or were 
outlined in optic nerve and spi-
nal cord schemes. Areas of pri-
mary demyelination are shown 
in green, lesions with dominant 
axonal loss, and secondarily 
demyelinated areas in blue, and 
cortical demyelination in brown. 
Shaded schemes indicate lack of 
sufficient information for lesion 
distribution
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of antigens and the subsequent activation and expansion of 
CD4+ T-lymphocytes [20]. Thus, nearly all of the models, 
which have so far been used, are biased towards a specific 
immune response mediated by MHC Class II restricted 
CD4+ T-lymphocytes. The disease induced by this sensiti-
zation process has been named experimental autoimmune 
encephalomyelitis (EAE), which is now one of the most 
widely used in vivo models to study immunology and brain 
inflammation. EAE can be induced in all vertebrates tested 
so far with a different degree of efficacy. Therefore, a wide-
spread spectrum of models with different specific features 
is now available [1], most commonly using mice, rats, and 
primates (see below). The enthusiasm for the EAE models 
in MS research varied over time. In the early stages (1930–
1960), the models have been seen as highly useful tools 
to study MS pathogenesis, but then, limitations became 
apparent, which indicated that such models are only use-
ful for the investigation of very specific disease-related 
Fig. 1  continued
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questions (1960–1990). The introduction of highly repro-
ducible EAE in mice, using myelin oligodendrocyte glyco-
protein MOG35–55 peptide for sensitization [111], offered 
to address questions on molecular disease mechanisms in 
transgenic and gene knock-out models which were sub-
sequently widely used by the research community. This 
enthusiasm, however, clouded the fact that mouse models 
are rather imperfect in mimicking the disease process of 
MS (see below).
Overall, the EAE models can be classified into differ-
ent types, which can be used for different specific research 
questions.
Passive T‑cell transfer models
Pioneer work by Phillip Paterson [123] showed that lym-
phocytes, which were retrieved from the peripheral 
immune system after sensitization of animals with brain 
tissue, are able to induce a neuroinflammatory disease in 
naïve recipients. Formal proof of this observation was pro-
vided by Ben Nun, Wekerle, and Cohen [13], who were 
able to isolate and propagate T-cell lines and clones, spe-
cific for myelin basic protein, which triggered an enceph-
alomyelitis in naïve recipient animals after intravenous 
transfer (Fig. 2). In subsequent studies, these results, orig-
inally obtained in Lewis rats, were expanded to other rat 
and mouse strains and to other CNS antigens, including 
other myelin, astrocyte, or neuronal proteins [166]. This 
passive transfer model is particularly useful to study the 
mechanisms controlling immune surveillance of the CNS, 
the induction of brain inflammation, and T-cell-mediated 
inflammatory tissue injury. These studies defined besides 
many other aspects the conditions, how T-cells are able to 
enter the CNS [46, 167], what entry routes into the brain 
and spinal cord they use [9, 133], how important their re-
activation state is within the CNS [77, 115], and to what 
extent the functional polarization of T-cells determines 
the extent, quality, and distribution of brain inflammation 
[127]. A major advantage of such passive transfer models 
is that the T-cells are already raised and expanded, and that 
the outcome of brain inflammation is not influenced by the 
afferent arm of specific immune activation in peripheral 
lymphatic tissue. The major shortcoming of this model is 
that it is essentially restricted to inflammation, mediated 
by CD4+ T-lymphocytes. Irrespective of animals, species, 
or strain, and of the antigen reactivity of the T-cells used, 
the passive transfer of CD4+ T-cells induces an inflam-
matory disease of the CNS with some and variable axonal 
injury but without widespread focal primary demyelination 
(Fig. 2, Table 1).
As will be discussed later, such passive transfer experi-
ments can also be performed with Class I MHC restricted 
CD8+ T-cells. Under these conditions, inflammation is 
associated with selective destruction of the target cells by 
cytotoxic T-lymphocytes, which may result in plaque-like 
demyelination, when the T-cells are directed against an 
antigen contained in oligodendrocytes [140] (Fig. 1). Simi-
lar models for auto-reactive B-cells are currently not avail-
able. They would be particularly interesting and important 
in the light of recent clinical trials in MS patients, showing 
a profound beneficial effect of peripheral B-cell depletion 
on the disease course [150].
Passive co‑transfer of auto‑reactive T‑cells and pathogenic 
auto‑antibodies
The intact blood brain barrier restricts diffusion of circu-
lating auto-antibodies into the brain. In addition, auto-
antibodies within the brain require immune activation of 
effector cells and/or the presence of complement factors 
forming the terminal membrane attack complex to pro-
duce tissue damage. One way to overcome this problem 
is to systemically inject the respective auto-antibody into 
animals, in which brain inflammation has been induced by 
passive transfer of auto-reactive encephalitogenic T-cell 
lines [96]. In this case, the T-cell reaction induces inflam-
mation with activation of macrophages and microglia, and 
allows the antibody and complement factors to diffuse into 
the brain or spinal cord at sites of inflammation and blood–
brain barrier damage. This paradigm has first been used to 
test the demyelinating potential of antibodies against mye-
lin oligodendrocyte glycoprotein in vivo [96]. It showed 
that under these conditions, the inflammatory reaction is 
associated with widespread primary demyelination, giving 
rise to demyelinated plaques with close similarities to those 
seen in MS. This model may also shed light on the con-
troversial discussion on the presence or absence of inflam-
mation in active MS lesions [8] (Table 1). It showed that 
in the presence of high titers of circulating demyelinating 
antibodies, a T-cell-mediated inflammatory response in 
the CNS is absolutely required to trigger the demyelinat-
ing lesions, but the number of transferred T-cells, which are 
necessary to start the disease, can be very low. Within the 
respective brain lesions, only an extremely small number 
of T-cells are present, despite very large plaque-like active 
demyelination [90]. A similar pathological scenario is also 
seen in chronic models of MOG-induced EAE after active 
sensitization, when the lesions are triggered by a coopera-
tion of encephalitogenic T-cells and demyelinating antibod-
ies (see below).
More recently, this model has also been used to define 
the pathogenetic potential of other antibodies, such as 
those directed against neurofascin or against aquaporin 
4 [25, 109]. The latter is now an important experimen-
tal model for neuromyelitis optica (NMO), which allows 
to define the pathogenetic role not only of patient-derived 
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anti-aquaporin 4 auto-antibodies, but also the role of aqua-
porin 4 reactive T-lymphocytes [129, 169]. A limitation of 
this model for NMO is that it has been so far not possible 
to raise a stable pathogenetic “true-autoimmune” aquaporin 
4 antibody response in rats or mice by active sensitization. 
In one of the latest attempts, reported by Kurosawa et al. 
[85], pathogenic murine aquaporin 4-specific antibodies 
were produced by immunization of aquaporin 4 deficient 
mice. Thus, experiments are most frequently performed 
with human antibodies, which induce an anti-human immu-
noglobulin G response, which may interfere with pathoge-
netic mechanisms in chronic disease conditions.
Active sensitization models
These models require active immunization with a CNS 
antigen together with a strong adjuvant (such as for 
instance complete Freund’s adjuvant, CFA [11, 75]). In 
mice, this alone is generally not sufficient and additional 
treatment of the animals with pertussis toxin is necessary 
[16]. The exact mechanism, how pertussis toxin augments 
the sensitization process, is still largely unknown. Sug-
gested potential mechanisms are the inhibition of periph-
eral T-cell anergy induction [76], a suppression of the 
function of regulatory T-cells [29], an effect on innate 
immunity [41], or direct effects on the blood brain barrier 
[99]. The most frequently used active sensitization model 
is induced in mice by sensitization with the MOG35–55 pep-
tide in CFA [111] (Fig. 1). This model is easy to induce and 
results in an acute or chronic inflammatory disease in the 
spinal cord, dependent upon the immunization procedure 
and the genetic background of the animals. Although this 
model is most popular for the analysis of molecular dis-
ease mechanisms in transgenic mouse strains, it has major 
limitations as a model for MS. It is a model for an acute or 
chronic inflammatory encephalopathy with primary axonal 
injury mediated by auto-reactive MHC Class II restricted 
CD4+ T-cells [78; 151; 118). Larger lesions are mainly due 
to massive axonal degeneration with secondary demyeli-
nation, while primary demyelination is sparse or absent, a 
pathological picture that is quite different from that seen in 
MS (Fig. 2). Another shortcoming of this model is that its 
pathology is largely confined to the spinal cord, with low 
affection of the brain stem and the cerebellum and very lit-
tle inflammation or tissue damage in the forebrain.
A disease, which more closely resembles MS, is induced 
by active sensitization of rats [156], guinea pigs [89], or 
primates [73] with the recombinant extracellular domain 
(amino acids 1–125) of myelin oligodendrocyte glycopro-
tein (MOG), with myelin or with brain tissue in CFA. The 
pathogenetic principle in these models is that they induce a 
CD4+ T-cell-mediated encephalitogenic response together 
with a demyelinating auto-antibody response against MOG 
[96]. The pathological hallmark in these models is the 
appearance of large confluent plaques of primary demy-
elination with partial axonal sparing, comparable to the 
lesions seen in MS patients (Figs. 1, 2) [156]. The extent 
of demyelination and the topographical distribution of the 
demyelinated lesions depend upon the genetic background 
of the animals [165]. Thus, in certain rat strains and in 
primates also, very large (subpial) cortical demyelinated 
lesions are seen, which are related to a chronic inflamma-
tory process in the meninges [131, 155] (Fig. 1). Overall, 
these models in many respects resemble the pathological 
changes in MS, although it has to be considered that anti-
MOG antibodies are, in general, not present in the serum 
of MS patients. When they are found in patients, they are 
mostly associated with clinical phenotypes, which are dis-
tinct from MS, resembling ADEM, aquaporin 4 negative 
NMO, or an atypical inflammatory demyelinating disease, 
which does not fulfill the diagnostic criteria for MS [79, 
147]. Thus, MOG-induced disease in experimental animals 
may be a perfect model for a MOG autoimmune syndrome 
in humans, which may be distinct from MS. In MS, demy-
elinating and neurotoxic activity have been described in 
sera and cerebrospinal fluid. Whether this is due to auto-
antibodies against so far undefined CNS antigens [23] or to 
Fig. 2  Basic patterns of pathology in different MS Models Part 1. 
Pure inflammatory models exemplified by passive transfer of CD4+ 
T-cells directed against myelin basic protein (MBP) in the Lewis rat. 
Spinal cord with massive inflammation reflected by the presence of 
perivenous inflammatory cuffs and diffuse infiltration of the tissue 
by T-cells and macrophages (a H&E; d CD3; e macrophage marker 
ED1). Sections stained for myelin (b, Luxol fast blue) or axons (c 
Bielschowsky silver impregnation) do not show demyelination or 
axonal loss, but there are some axons with accumulation of amyloid 
precursor protein (f APP), indicating a mild-to-moderate degree of 
(in part reversible) axonal injury. Models with chronic inflammatory 
axonopathy leading to focal lesions with secondary demyelination. 
As an example, spinal cord pathology of a NOD mouse with chronic 
EAE, 90 days after active sensitization with myelin oligodendrocyte 
glycoprotein peptide (MOG35–55), is shown. A confluent inflamma-
tory demyelinated lesion is present in the dorsal column of the spi-
nal cord (g H&E, h Luxol fast blue). There is nearly complete axonal 
loss within the lesion (i, n Bielschowsky silver impregnation); the 
lesion is infiltrated by a moderate number of T-cells (j, l CD3) and 
shows a broad rim of activated macrophages at the lesion edges (k 
Mac3); ongoing tissue destruction is shown by the presence of mye-
lin protein reactive degradation products in macrophages (m PLP) 
and by the presence of numerous axons with disturbed fast axonal 
transport (intra-axonal accumulation of amyloid precursor protein; o 
APP). Chronic EAE in the DA rat 60 days after active immunization 
with full-length recombinant myelin oligodendrocyte glycoprotein as 
a model for extensive inflammatory demyelinating disease; profound 
inflammation (p H&E) and widespread confluent demyelination (q 
Luxol fast blue), but nearly complete axonal preservation (r Biels-
chowsky silver impregnation) and pronounced astrogliosis (s GFAP); 
the areas of active demyelination are highly infiltrated by mac-
rophages (t ED1), but contain only very few T-lymphocytes (u CD3); 
and myelin sheaths and myelin degradation products in macrophages 
are decorated by activated complement (v C9neo antigen)
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inflammatory mediators other than immunoglobulin [98] is 
currently unresolved (Table 1).
Spontaneous models of EAE
Diseases, which are induced by passive transfer of T-cells 
or by active immunization, offer only limited possibili-
ties to identify immunological mechanisms, which are 
responsible to initiate the disease process or which regu-
late relapses. To overcome these problems, new models 
have been created, in which animals develop a spontane-
ous inflammatory demyelinating disease. This can be done 
by transgenically expressing a T-cell receptor of encepha-
litogenic T-cells, which recognizes a brain antigen, such 
as MOG [17]. These animals are born normal and when 
kept under the conventional breeding and housing condi-
tions develop a spontaneous inflammatory or inflammatory 
demyelinating disease several months after birth (Fig. 1), 
in a frequency of up to 80 %, depending on mouse strain 
and gender [130]. In addition, such animals can be crossed 
with B-cell receptor transgenic mice, which mount an 
auto-reactive (demyelinating) antibody response [18, 83]. 
However, despite the presence of potentially demyelinat-
ing antibodies in these double transgenic mice, primary 
demyelination in the CNS lesions is sparse in contrast to 
those in rats or primates with a demyelinating anti-MOG 
antibody response and no complement activation is seen in 
the lesions [83]. As in other mouse models, the pathology 
of the lesions shows preferential axonal loss with second-
ary demyelination. Thus, mouse complement activation 
appears to be less efficient in comparison to that of rats, 
guinea pigs, or primates. This view is also supported by the 
observation that the induction of lesions in the mouse after 
focal injections of (human) aquaporin 4 or MOG antibodies 
requires the simultaneous presence of human complement 
[138, 139].
Spontaneous EAE models were found particularly use-
ful for research on the role of gut microbiota in the induc-
tion of brain inflammation [15]. When such animals are 
kept under germ free condition, no disease develops. How-
ever, disease is triggered when their gut is colonized with 
the normal gut flora. Such models can be used to identify 
the bacterial components of the gut flora, which trigger 
and expand an encephalitogenic T-cell response. Another 
interesting observation in such a model was, that in SJL 
mice, but not in C57BL/6 mice, the presence of the trans-
genic encephalitogenic T-cells may trigger an endogenous 
demyelinating anti-MOG antibody response [130]. These 
results help to explain the mechanisms of antigen/epitope 
spreading in the induction of chronic brain inflamma-
tion, which has been shown in several other EAE models 
before. Overall, however, the same limitation, as discussed 
before, applies also for these models. They describe CD4+ 
T-cell-mediated inflammatory processes of the CNS. As in 
other mouse models, demyelination is mainly following 
axonal pathology with a little primary demyelination. To 
what extent findings obtained in these models are relevant 
for MS has to be shown in studies involving patients.
Humanized EAE models
Species-related differences in the molecular function of 
proteins are a problem, which require transgenic expres-
sion of the respective molecules in experimental ani-
mals in vivo. Since myelin proteins are highly conserved 
between different species, this problem essentially con-
cerns antigen presentation. As an example, T-cells only 
recognize their respective antigen, when it is processed 
in antigen presenting cells and presented in the context 
of major histocompatibility complex (MHC) molecules, 
which are highly polymorphic and different between ver-
tebrate strains or species. Thus, the determination of the 
encephalitogenic potential of auto-reactive T-cells, iden-
tified in patients, has to be validated in animals, which 
express the respective human MHC proteins. This can be 
achieved in humanized mouse models [12, 42]. Respec-
tive studies of EAE, induced in human MHC Class I or 
II transgenic animals, have contributed to define antigenic 
peptides, which may be encephalitogenic in humans. How-
ever, encephalitogenicity is not only regulated by antigen 
presentation, but also involves antigen processing and the 
involvement of adhesions molecules and chemokines, nec-
essary for T-cell migration into the CNS. Thus, an ideal 
experimental design would require multiple transgenic 
manipulations, in which all the molecules involved in this 
process are humanized. Similar rules also apply for the 
validation of any other molecular pathway involved in the 
pathogenesis of a disease, such as MS. It is obvious that 
such an approach is highly complicated and technically 
challenging, and so far, its use in experimental pathogen-
esis research is very limited.
Models of focal inflammatory demyelinating lesions in the 
CNS
All the models described above show inflammatory demy-
elinating lesions, which are dominantly located in the spi-
nal cord. The location of the lesions is randomly distributed 
with a certain predilection for the lumbar/sacral spinal cord, 
but for analyzing molecular events in vivo by dual photon 
laser microscopy or functional changes by electrophysiol-
ogy, the precise and reproducible localization of the lesion 
within a specific area of the CNS is required. It has already 
been shown in the earliest studies on EAE that inflamma-
tory lesions are precipitated into areas of concomitant brain 
injury, such as direct trauma, thermal injury lesions, or 
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cyanide-induced demyelinating lesions [92, 93]. This has 
recently been expanded by the observation that inflamma-
tion is also precipitated into demyelinated lesions induced 
by cuprizone [143]. Interestingly, when EAE pathology is 
precipitated into forebrain lesions, this is associated with 
less severe spinal cord or brain stem lesions [92]. Thus, the 
shift of EAE lesions from a site relevant for clinical deficit 
into a clinically silent area, which may happen after focal 
injection of a therapeutic agent, such as, for instance, stem 
cells, into the forebrain may erroneously mimic therapeutic 
efficacy.
A similar approach has been used by focal stereotactic 
injection of a small amount of pro-inflammatory cytokines 
in animals, which are pre-sensitized with MOG1–125. The 
latter induces an encephalitogenic T-cell response and a 
demyelinating anti-MOG antibody response in the periph-
eral immune system of the sensitized animals (Fig. 1). 
Focal injection of cytokines precipitates inflammatory 
demyelination at a defined site of the CNS, located around 
the injection site. As an example, this strategy was used to 
define, in detail, the cellular events occurring in cortical 
EAE lesions [54, 112].
Focal CNS injections can also be used for testing the 
pathogenic potential of inflammatory mediators, which do 
not sufficiently pass the intact blood brain barrier in nor-
mal animals. This has, for instance, been used for testing 
the pathogenic potential of demyelinating or aquaporin 4 
reactive auto-antibodies in vivo and to analyze the effector 
mechanisms, such as complement activation or antibody-
dependent cellular cytotoxicity, in the process of antibody-
mediated tissue injury [138, 139, 162].
Using a comparable approach, mechanisms of innate 
immunity in the pathogenesis of demyelination have been 
elucidated. Focal injection of lipopolysaccharide into the 
spinal cord induces a transient inflammatory reaction dur-
ing the first days after application, which is followed by 
the formation of focal inflammatory demyelinating lesions 
after a delay of several days [43, 106]. The latter is asso-
ciated with profound microglia and macrophage activa-
tion, profound alterations of astrocyte function [148], and 
a mechanism of tissue injury, which involves oxygen radi-
cal-mediated cell injury and hypoxia-like cellular damage, 
thus, reproducing some key features of lesion pathology 
seen in a subset of multiple sclerosis patients and lesions 
[38].
EAE models for primary or secondary progressive MS
After active immunization, EAE animals develop either 
an acute monophasic or a chronic disease, which may last 
for several months. In the Biozzi ABH mouse, the chronic 
course may present with relapses or remission [7] or a dis-
ease, which has been described as chronic progressive [3, 
60]. However, in these models, the chronic disease is not 
clinically progressive but reflects stable disease on a mod-
erate-to-high level of neurological disability. In an attempt 
to reproduce the profound axonal and grey matter injury 
seen in progressive MS, Biozzi mice were sensitized with 
neurofilament-L [68, 69]. This procedure resulted in an 
acute or subacute neuroinflammatory disease with severe 
axonal pathology also targeting the grey matter, appar-
ently mediated by CD4+ T-cells directed against neuro-
filament. However, also this model did not reproduce the 
slow progressive disease characteristic for the progressive 
stage of MS. More recently, it has been shown that a CD4 
T-cell-driven autoimmune disease is also induced due to 
molecular mimicry between myelin oligodendrocyte gly-
coprotein35–55 and neurofilament-L [84]. Whether, in these 
models, neurodegeneration is due to direct interaction 
between auto-reactive T-cells and neurons or by activated 
microglia is currently unresolved.
Another study analyzed the effect of age in the induction 
of autoimmune encephalomyelitis in Biozzi mice [125]. 
This study reports the induction of a primary progressive 
like disease course, when animals were sensitized with 
spinal cord homogenate in complete Freund’s adjuvant, 
although details on the clinical course are not provided in 
this study. In contrast to the situation in primary progres-
sive MS in humans, this disease was characterized by very 
prominent T-cell infiltration in the lesions, which exceeded 
that seen in comparable models of relapsing or secondary 
progressive disease.
Profound microglia activation is associated with progres-
sion of demyelination and neurodegeneration in the brain 
of MS patients. One attempt to create a model for progres-
sive MS was, thus, to induce EAE in mice with a genetic 
background of high innate immunity activation. This was 
achieved using the non-obese diabetic (NOD) mouse 
strain [10] (Figs. 1, 2). Such animals develop chronic, in 
part progressive EAE, over a time period of 70 days with 
an incidence of 90 % [94, 95]. Although these mice have 
large lesions in the spinal cord, the pathological alterations 
are not essentially different from those seen in other mouse 
EAE models (inflammation, dominant axonal injury with 
secondary demyelination, and little primary demyelina-
tion). As in MS, oxidative injury appears to play a major 
role in chronic tissue injury, shown by the neuroprotective 
action of anti-oxidant treatment [10].
One hypothesis, explaining neurodegeneration in pro-
gressive MS is that inflammation starts a cascade of events 
in the brain, which leads to ongoing neurodegeneration 
that becomes independent from the inflammatory process. 
This question was addressed in the chronic EAE model in 
Biozzi/ABH mice described above. In this model, inflam-
mation was blocked by tolerization with a CD4 T-cell-
depleting monoclonal antibody at different stages of the 
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chronic disease [60]. This study shows effective reduction 
in the inflammatory response, absence of active demyelina-
tion, and increased remyelination in the tolerized animals. 
Despite these findings, evidence was provided for ongo-
ing and progressive axonal and neuronal degeneration up 
to 50 days after tolerization [60]. Ongoing axonal and neu-
ronal degeneration was not reflected by a chronic progres-
sive worsening of neurological disease. In this context, one 
has to consider that after the transection of axons within 
a focal lesion, Wallerian degeneration and retrograde or 
anterograde neuronal degeneration take place and this is 
a very slow process. Thus, the detection of axonal pathol-
ogy and progressive loss of axons and neurons may merely 
reflect the late consequences of lesions, which developed 
during the active phase of the disease, but do not model 
progressive disease in MS.
Cortical (subpial) demyelination is a key feature of the 
pathology of progressive MS. It is already seen in the early 
disease stages [101] but massively increases, when patients 
develop progressive disease [86] (Fig. 1). Cortical demy-
elination is associated with neuronal degeneration [102] 
and this appears to be a major driving force for secondary 
Wallerian degeneration in the white matter. In fact, dif-
fuse pathology of the white matter in MS patients corre-
lates better with the extent of cortical lesions than with the 
size, destructiveness, and location of white matter plaques 
[86]. Thus, cortical pathology appears to be a very impor-
tant driving force for chronic progressive neurodegenera-
tion in the MS brain. Active cortical demyelination occurs 
at sites of meningeal inflammation. In patients with severe 
and aggressive disease, the inflammatory aggregates in the 
meninges structurally resemble tertiary lymph follicles 
[102]. The question, thus, arises to what extent meningeal 
inflammation and subsequent subpial cortical demyelina-
tion can be modeled in EAE animals.
In most chronic EAE animals, meningeal inflammation 
is sparse and cortical demyelination is absent. There are, 
however, some exceptions. In specific MOG immunized 
mouse strains, extensive meningeal inflammation with for-
mation of tertiary lymph follicle-like structures is seen. The 
formation of these follicles is augmented by the expres-
sion of podoplanin in Th17 T-cells and in meningeal cells, 
a molecule which is crucial for the development of second-
ary lymphoid follicles [126]. However, meningeal inflam-
mation in this mouse model was not followed by MS-like 
subpial demyelination.
Extensive subpial demyelination, associated with menin-
geal inflammation, has been found in selected EAE models 
in rats and primates after active sensitization with MOG1–
125 [131, 155] (Fig. 1). More detailed immunopathological 
studies of such lesions suggest that they are triggered by 
inflammatory mediators in cooperation with demyelinat-
ing antibodies, which, both, are produced in the meningeal 
inflammatory infiltrates, diffuse into the cortex, and induce 
demyelination at distant sites in association with micro-
glia activation. A very similar scenario has been suggested 
to explain the pathogenesis of subpial cortical lesions in 
MS patients. Active cortical lesions are associated with 
meningeal inflammation, which, in its most severe form, 
may reflect inflammatory cell aggregates with features 
of tertiary lymph follicles. Whether cortical lesions in 
MS patients are driven by demyelinating auto-antibodies, 
which have been detected in the cerebrospinal fluid of MS 
patients [23], or by other so far unidentified inflammatory 
mediators [98] is currently not clear.
Recently, chronic microglia activation, excessive oxida-
tive stress, mitochondrial injury, and amplification of oxi-
dative stress by iron liberation from degenerating oligo-
dendrocytes have been suggested as a major driving force 
of demyelination and neurodegeneration in MS, and this 
mechanism seems to be particularly important in the pro-
gressive stage of MS [103]. Similar tissue alterations are, 
in part, also present in EAE models, but there are major 
differences in their degree in comparison to MS. Expres-
sion of molecules involved in oxygen radical production 
is prominent in macrophages within the EAE lesions, but 
in contrast to the human CNS, they are sparse or absent in 
microglia at the lesion edge of the normal appearing white 
or grey matter [144]. Axonal degeneration in acute mouse 
EAE models involves oxidative stress and mitochondrial 
injury [118], but the widespread mitochondrial injury 
with deletion of mitochondrially encoded genes, which 
is a characteristic finding in MS [28, 104], has so far not 
been seen in EAE. Finally, iron accumulation in myelin 
and oligodendrocytes occurs in an age-dependent manner 
in the human brain and iron is liberated into the extracel-
lular space in actively demyelinating MS lesions [59]. In 
rodents, a limited degree of iron accumulation is seen at the 
end of the animal’s life span in the basal ganglia, but not 
in the rest of the brain or the spinal cord, typically targeted 
by the inflammatory process in EAE, and it is completely 
absent in young adult animals preferentially used in EAE 
experiments [144].
For all these reasons, progressive MS is reflected only to 
a very limited degree in currently available EAE models.
EAE models driven by MHC Class I restricted CD8+ 
T‑cells
The abundance of CD8+ T-cells in MS lesions suggests that 
these cells may play an important role in the pathogenesis 
of the disease. So far, however, it proved to be very difficult 
to induce a pathogenic CD8+ T-cell autoimmune response 
by active immunization. One observation, which suggests 
that this may be possible, came from a study, which ana-
lyzed, in detail, the immunology and immunopathology 
235Acta Neuropathol (2017) 133:223–244 
1 3
of EAE in C57BL/6 mice, induced by sensitization with 
MOG35–55 [158]. In this study, a prominent MOG-specific 
CD8+ T-cell response was observed and CD8+ T-cells, 
although not in a completely pure form, modified brain 
inflammation after passive transfer. A contribution of 
MOG-specific CD8+ T-cells to brain inflammation has also 
been reported in T-cell receptor transgenic animals [2] and 
in a humanized mouse model [107], (Table 1).
Another approach isolated and propagated auto-reactive 
CD8+ T-cells from mice, actively sensitized with myelin 
basic protein, and transferred them into naïve recipients. 
This induced clinical disease and brain inflammation in the 
recipient animals [70]. In other studies, foreign antigens 
(ovalbumin or influenza hemagglutinin) were transgeni-
cally expressed in different cells of the CNS and disease 
was induced by the passive transfer of T-cells from trans-
genic animals, which express a T-cell receptor directed 
against the respective pathogenic epitope of ovalbumin or 
hemagglutinin [27, 116, 140] (Fig. 1). Taken together, these 
studies show that auto-reactive Class I MHC restricted 
T-cells can induce brain inflammation without the help 
of other T-cell populations in the immune repertoire. The 
studies have further shown that these CD8+ T-cells are 
cytotoxic and destroy the cells within the CNS, which 
Fig. 3  Basic patterns of pathology in different MS models Part 2. 
MHV-induced spinal cord pathology as an example for inflammatory 
demyelinating lesions with extensive oligodendrocyte and astrocyte 
loss; large confluent demyelinated lesions in the lateral column of 
the spinal cord with inflammation and tissue edema (a H&E), com-
plete demyelination (b Luxol fast blue), and nearly complete axonal 
preservation (c, d Bodian silver impregnation), but nearly complete 
loss of astrocytes (e GFAP); some of the astrocytes at the lesion edge 
contain virus antigen (f). The cuprizone model as an example for 
toxic demyelination; large hyper-cellular demyelinating lesion in the 
corpus callosum after 6 weeks of cuprizone exposure (g H&E). The 
lesion shows complete demyelination (h Luxol fast blue) and only 
mild or moderate axonal loss (i, l Bielschowsky silver impregnation); 
the site of active demyelination is highly infiltrated by macrophages 
and activated microglia (j Mac3); oligodendrocytes are lost within 
the areas of active demyelination and only preserved in the areas with 
intact myelin (k CNPase)
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contain the cognate antigen. In case of CD8+ T-cells rec-
ognizing an antigen within oligodendrocytes, this leads to 
focal plaques of primary demyelination and oligodendro-
cyte loss, but other models, targeting astrocytes [27] or 
neurons, are also available [143].
However, transfer of CD8+ T-cells in general requires 
much higher cell numbers to induce brain inflammation 
and tissue injury compared with CD4+ T-cells. This may in 
part be explained by the observation that oligodendrocyte-
specific CD8 cells can enter the normal brain and be elimi-
nated by apoptosis in the course of their interaction with 
normal oligodendrocytes. However, when they enter the 
inflamed brain, they are cytotoxic [117]. Using humanized 
transgenic mouse models, it has been shown that CD8+ 
T-lymphocytes carrying a human T-cell receptor against 
proteolipid protein, which has been derived from T-lym-
phocytes of an MS patient, also can induce brain inflamma-
tion in vivo [51]. Overall, however, data on the pathogenic-
ity of auto-reactive CD8+ T-cells are limited in comparison 
to those available for CD4+ cells.
A major unresolved question of experimental MS 
research is that currently, no models of B-lymphocyte-
associated brain inflammation are available. It is not clear, 
whether B-cells alone may initiate and drive an acute or 
chronic inflammatory reaction in the CNS, whether they 
are just secondarily recruited into T-cell-mediated inflam-
matory foci and in what way they contribute to the induc-
tion and propagation of tissue injury, independent from 
antibodies.
Models of virus‑induced inflammatory demyelination
EAE is an autoimmune disease of the CNS, which is 
induced by active immunization with brain antigens 
together with potent immune-stimulating adjuvants, by 
passive transfer of primed T-cells or by transgenic expres-
sion of an autoantigen recognizing T-cell receptor. None 
of these scenarios give clues on how the disease may be 
triggered in MS patients. It was, thus, interesting to see 
that certain virus infections in animals may give rise to 
an inflammatory demyelinating disease with similarities 
to MS [37]. So far, however, no MS-specific virus infec-
tion has been found, although some indirect evidence sug-
gests that infection with Epstein Barr Virus or activation of 
endogenous retroviruses may play a role in its pathogenesis 
[4, 120].
Despite the current lack of evidence for an MS-specific 
virus infection, the study of virus induced experimen-
tal models of inflammatory demyelination may provide 
insights into the basic mechanisms, how such a pathologi-
cal condition in the brain and spinal cord could be induced 
or propagated, and such studies may provide additional 
information on mechanisms of MS-related inflammation, 
demyelination and neurodegeneration [37]. A major draw-
back for virus models, however, is their very complex 
pathogenesis, involving direct virus induced effects, anti-
viral immunity, and additional autoimmune mechanisms 
[37], and the effects of these different pathogenetic com-
ponents are difficult to dissect. The two most widely used 
viral MS models are chronic encephalomyelitis induced by 
the Theiler’s virus or by the MHV corona virus.
Chronic demyelinating encephalomyelitis induced by the 
Theiler’s virus (TMEV)
The model is induced by the direct intracerebral infec-
tion of the animals with the virus. This leads to an acute 
encephalomyelitis in most infected animals, and disease 
course and mortality depend upon the virulence of the 
virus strain used for infection and the genetic ability of the 
host animals to mount a specific anti-viral T-cell response. 
Using specific virus strains (BeAn strain or Daniel’s strain) 
in mice with specific MHC haplotypes (H-2q,r,s,v,f,p), the 
acute encephalitic phase is followed by a chronic demyeli-
nating disease, which mainly affects the spinal cord [37]. 
Virus antigen is cleared from the brain, but persists in the 
spinal cord in oligodendrocytes [136] and macrophages 
[97]. The spinal cord lesions are characterized by chronic 
inflammation, the formation of confluent plaques of pri-
mary demyelination, a variable extent of axonal injury, 
and remyelination, the latter dependent upon the genetic 
background of the mouse strain [19, 137]. Inflammatory 
infiltrates consist of a mixture of CD4+ and CD8+ T-cells, 
B-cells, and plasma cells [119, 122]. Active demyelina-
tion occurs at sites of microglia activation and macrophage 
infiltration. Thus, the lesions share essential features with 
those present in MS (Table 1).
The TMEV model has extensively been used to study 
the mechanisms of viral clearance from the CNS. It has 
been shown that in the early stage, the immune response 
is mainly directed against the virus [114], but that at later 
stages, additional autoimmune reactions are induced, most 
likely through the mechanisms of antigen/epitope spread-
ing [121]. The model also made it possible to define the 
role of different lymphocyte populations in the pathogenic 
process. While CD8+ T-cells were instrumental for virus 
clearance together with a virus-specific antibody response, 
CD4+ T-cells were involved in inflammatory demyelina-
tion [114]. In contrast, depletion of CD8+ T-cells reduced 
chronic disease in parallel with chronic axonal injury and 
neurodegeneration [67, 134]. A major difference to what is 
seen in MS is that a B-cell depleting therapy augments the 
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early inflammatory as well as the late inflammatory demy-
elinating disease, and this was associated with an increase 
in viral load within the CNS [55]. The complexity of the 
disease process in the TMEV models is also reflected by 
the outcome of treatment studies with induced regula-
tory T-cells [108]. Regulatory T-cells increased disease in 
the early stage of the disease by suppressing the anti-viral 
response, but showed a beneficial effect in the late inflam-
matory demyelinating stage.
Chronic inflammatory demyelinating disease induced 
by the Mouse Hepatitis (corona) Virus (MHV)
The isolation of MHV from the brain of a paralyzed mouse, 
presenting with disseminated encephalomyelitis and 
prominent demyelination [5], suggested that inflammatory 
demyelinating diseases may be triggered by viral infec-
tion. In the subsequent years, MHV-induced demyelinating 
encephalomyelitis was developed as a major experimental 
animal model of MS. MHV is a large corona virus, which 
may induce hepatic, enteric, respiratory, or neurologi-
cal disease, depending upon the virus strain. Neurological 
disease occurs after intracranial or nasal infection with 
a neurovirulent strain [14]. It develops in two phases: the 
first phase starts within days after infection and results in 
a virus-induced panencephalitis. When the animals recover 
from this first phase, a second phase may appear about 
4 weeks later, characterized by neuroparalytic disease with 
inflammatory demyelinating lesions. Virus is largely elimi-
nated from the brain at the end of the first phase, but viral 
RNA persists within the late lesions throughout the entire 
disease. The virology of JHM-induced brain disease has 
recently been summarized in an excellent review [14]. For 
this reason, we will only discuss some aspects related to 
the chronic inflammatory demyelinating disease within this 
chapter.
The pathology of the disease is characterized by chronic 
inflammation and the formation of confluent plaques of pri-
mary demyelination with variable extent of acute axonal 
injury and axonal loss (Fig. 3). Virus antigen is seen mainly 
in the acute phase of the disease and is present in multi-
ple different cell types, including macrophages, micro-
glia, astrocytes, oligodendrocytes, and neurons. When the 
animals recover from the acute phase, virus in the brain 
is largely cleared, although viral RNA persists in the tis-
sue throughout the chronic demyelinating phase. However, 
viral protein expression is sparse or undetectable [153]. 
Inflammatory infiltrates consist of T-lymphocytes and 
activated macrophages/microglia [154, 168]. Intrathecal 
production of immunoglobulins also suggests a major con-
tribution of B-cells and plasma cells to the inflammatory 
process [39]. Various different immune mechanisms con-
tribute to virus clearance from the CNS, including innate 
immune mechanisms, CD8+ and CD4+ T-cells, and anti-
viral antibodies. Originally, it was suggested that demy-
elination is a result of lytic oligodendrocyte infection [88], 
but with application of immune-deficient animal models, 
it became clear that immune-mediated mechanisms may 
be more important [66]. They include antigen-independ-
ent (bystander) destruction of oligodendrocytes by CD8+ 
T-cells [34, 36] and gamma-delta T-cells [35] or recogni-
tion of virus antigen on oligodendrocytes by specific anti-
viral antibodies [80] (Table 1). The mechanisms of tissue 
injury may, however, in part depend upon the genetic back-
ground of the animal and the virus strain of MHV. From 
all these data, there is strong support for the view that the 
immune mechanisms, which are involved in virus clearance 
and the induction of inflammatory demyelination, are dif-
ferent. This view is also supported by the finding that treat-
ment of MHV-infected animals with the immunomodula-
tory drug fingolimod (FTY720) increases disease severity 
and viral load in the CNS, but reduces the severity of the 
demyelinating process [22]. Whether the immune-medi-
ated damage is due to a bystander effect of inflammation 
or to virus-induced autoimmunity is currently not resolved. 
However, it has been shown that MHV infection may trig-
ger an encephalitogenic T-cell-mediated autoimmune 
response against myelin basic protein [164] or proteolipid 
protein [33]. An interesting difference between MHV mod-
els and EAE is that the chronic virus-induced inflamma-
tory demyelination is associated with a massive microglia 
activation, which is seen in the entire brain and spinal cord, 
and is characterized by expression of oxygen radical pro-
ducing enzymes in microglia even at the lesion edge and 
in the normal appearing white matter, and by extensive 
oxidative injury in active lesions [144]. In addition, pro-
found astrocyte degeneration may be present, possibly due 
to virus infection of these cells. Astrocyte dysfunction may 
contribute to the pathogenesis of oligodendrocyte loss and 
demyelination. As in toxic models of demyelination with 
profound astrocyte degeneration, such lesions are preferen-
tially repaired by Schwann cell remyelination.
Until recently, JHM infection has been a common threat 
in laboratory animal (rodent) colonies [65]. Although 
this most commonly took place with enteric virus strains, 
which do not affect the CNS, some caution is warranted. 
In a study on EAE, induced by passive transfer of auto-
reactive T-cells, very unusual large and destructive lesions 
were noted in the spinal cord. This was present in animals 
with MHV antibodies in the circulation and further virolog-
ical analysis revealed coronavirus replication in the lesions 
[32].
One of the major advantages of virus-induced models of 
inflammatory demyelinating diseases is that they are caused 
by the infectious process and not by an active sensitiza-
tion with brain tissue. This may be a more natural process 
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providing information on the etiology of the disease pro-
cess in humans. However, despite extensive investigations 
of these models, key aspects have so far remained unre-
solved. It is likely, but not finally proven, that the chronic 
inflammatory process in these models is maintained by the 
persistence of low amounts of virus in the brain, but that 
the further tissue damage involves adaptive and innate 
immune mechanisms, different from those responsible for 
infection control.
Models of toxic demyelination
Primary demyelination is a pathological hallmark, distin-
guishing MS from other inflammatory diseases of the cen-
tral nervous system. To identify new therapeutic strategies, 
targeting de- and remyelination requires in depth knowl-
edge of the mechanisms involved in these processes [50]. 
Such information can best be obtained in models of toxic 
demyelination, which are not complicated by changes in 
the CNS due to inflammatory processes driven by adaptive 
immunity. The most frequently used model of toxic demy-
elination is induced by systemic exposure of the animals to 
cuprizone [56, 132]. Other models include the focal injec-
tion of lysolecithin [58, 74] or of ethidium bromide into 
specific white matter tracts [21]. Research in these mod-
els has provided seminal insights into metabolic processes 
involved in myelin destruction and repair (for review, 
see: [49, 50, 132], and was important for in vivo imaging 
of demyelinated lesions by magnetic resonance imaging 
[128], for determining the neuroprotective effect of remy-
elination [49], and for testing therapies aimed to promote 
remyelination (Table 1).
Cuprizone induced de‑ and remyelination
The basic features of the cuprizone model, including meta-
bolic and inflammatory mechanisms of de- and remyelina-
tion, have recently been summarized in detailed and com-
prehensive review articles [56, 132], and therefore, only 
some key characteristics related to the value of this model 
for MS research will be covered here. Cuprizone is a cop-
per chelating drug, which triggers apoptosis in oligoden-
drocytes and induces demyelination through mechanisms 
of oxidative injury. The processes of de- and remyelination 
are further amplified or modified by inflammatory mecha-
nisms, involving microglia and astrocytes [56]. Most mod-
els apply cuprizone in C57BL/6 mice for 4 weeks, which 
induces demyelination followed by rapid and extensive 
remyelination [63]. However, demyelinating lesions can be 
induced in many different mouse strains and also in other 
animal species, such as, for instance, rats, guinea pigs or 
hamsters [132]. The predictable location in the corpus cal-
losum (Fig. 3) and time course of the lesions in this model 
provide an excellent background to define the molecular 
mechanisms promoting de- and remyelination. However, 
the rapid and extensive spontaneous remyelination after 
short-term cuprizone exposure imposes limitations for the 
use as an experimental MS model. Thus, when using this 
model in the development of new remyelination-promot-
ing therapies, it has to be kept in mind that the respective 
studies show an acceleration of the remyelinating process, 
but do not correct for a permanent remyelination failure 
characteristic of MS lesions particularly in the progressive 
stage of the disease. However, even when the cuprizone 
lesions become fully remyelinated, progressive neurode-
generation may ensue. This is reflected by long-term and 
progressive decline in motor performance of the animals, 
associated with ongoing axonal injury in (re)myelinated 
fibers [105].
To overcome the problem of rapid remyelination, a sec-
ond model has been developed by exposure of animals to 
cuprizone for 12 weeks. In this model, chronic demyeli-
nated lesions are induced with little remyelination [110]. 
Impaired remyelination seems to be due to different fac-
tors, such as the depletion of the oligodendrocyte progeni-
tor cell population, changes in the focal environment of 
cytokines involved in proliferation, or differentiation of 
progenitor cells or factors which inhibit their migration into 
the lesions [132]. Similar factors have been proposed to 
explain in part remyelination failure in MS and have also 
been implicated in age-related decline of the remyelination 
capacity [40, 149].
Models of focal toxin‑induced demyelination
Lysolecithin, injected into white matter tracts of the CNS, 
induces focal plaques of demyelination due to a direct 
(detergent) action of the toxin, which damages the lipid 
membrane-rich myelin sheath [74]. It is a highly reproduc-
ible model of primary demyelination, which has the advan-
tage of triggering a focal lesion at a defined location within 
the CNS. As in other toxic models of demyelination, the 
phase of myelin destruction is rapidly followed by remyeli-
nation, although the speed and degree of remyelination are 
age-dependent [30, 48]. Age-related insufficiency of remy-
elination appears to be due to epigenetic control of oligo-
dendrocyte differentiation inhibitors [149], to impairment 
of the recruitment of different oligodendrocyte progenitor 
subsets [31], and to insufficiency of macrophages to clear 
the remyelination-inhibiting myelin debris [82]. These 
age-related effects on remyelination capacity appear to be 
highly relevant for remyelination failure in the progressive 
stage of MS.
Another focal model of demyelination used the focal 
injection of ethidium bromide into white matter tracts [21]. 
This leads to degeneration not only of oligodendrocytes but 
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also of astrocytes. With this model, it was shown that oli-
godendrocyte remyelination requires the presence of astro-
cytes. When absent, the lesions are repaired by Schwann 
cells. This may explain the extensive Schwann cell remy-
elination seen in some patients with neuromyelitis optica 
[71].
There is no doubt that toxic models provided the major 
clues for the understanding of molecular mechanisms of 
de- and remyelination. They showed that remyelination 
not only improves the function of axons, but also that it is 
neuroprotective. They also showed that the mechanisms of 
remyelination are highly complex and require the presence 
of progenitor cells, which are capable to perform the task, 
and a finely tuned expression of stimulatory and inhibi-
tory cytokines or growth factors. To determine the extent, 
to which these factors or mechanisms are relevant for MS 
requires analysis of respective lesions in the patients and 
the careful validation of the therapeutic potential of the fac-
tors in MS in clinical trials.
Conclusions
Although no single experimental model reproduces all 
aspects of multiple sclerosis in a single animal disease, a 
very large spectrum of different models is currently avail-
able, which covers individual aspects and mechanisms rel-
evant for disease pathogenesis. The selection of the right 
model for MS research, thus, largely depends upon the 
specific question, to be addressed. Regarding testing of 
new therapeutic strategies, these models may provide proof 
of principle that the respective approach provides positive 
effects in vivo, but many treatments tested positively in 
these experimental models failed in human clinical trials. 
However, such studies are indispensable to recognize as far 
as possible potential harmful side effects of new drugs in 
the inflamed or damaged CNS.
There are, however, key aspects of multiple sclerosis 
pathology and pathogenesis, including the role of CD8+ 
T-cells and B-cells, and the mechanisms of demyelina-
tion and tissue damage in the progressive stage of MS, 
which are so far covered in experimental models only to a 
very limited degree. Thus, as summarized in Table 2, new 
experimental models have to be developed to address these 
questions.
In addition, strict rules of experimentation have to be 
followed to achieve definite and reproducible results. This 
appears to be highly important, since reproducibility of 
published experimental studies has sometimes been a prob-
lem, and many results from such studies have failed to 
show comparable effects, when tested in patients. Recently 
guidelines, which set the standard for publication and grant 
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but similar rules also apply for the other models described 
in this review.
Acknowledgments Open access funding provided by Medical Uni-
versity of Vienna. The study was funded by the Austrian Science Fund 
(FWF), Projects P25240-B24 (MB) and P27744-B27 (HL).
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. Alvord EC (1970) Acute disseminated encephalomyelitis and 
“allergic” neuroencephalopathies. In: Vinken PY, Bruyn GW 
(eds) Handbook of clinical neurology, vol 9. Elsevier, New 
York, pp 500–571
 2. Anderson AC, Chandvaskar R, Lee DH, Sullivan JM, Solomon 
A, Rodriguez-Manzanet R, Greve B, Sobel RA, Kuchroo VK 
(2012) A transgenic model of central nervous system autoim-
munity mediated by CD4+ and CD8+ T and B cells. J Immunol 
188:2084–2092
 3. Anderson JM, Hampton DW, Patani R, Pryce G, Crowther 
RA, Reynolds RA, Franklin RJ, Giovannoni G, Compston DA, 
Baker D, Spillantini MG, Chandran S (2008) Abnormally phos-
phorylated tau is associated with neuronal and axonal loss in 
experimental autoimmune encephalomyelitis and multiple scle-
rosis. Brain 131:1736–1748
 4. Ascherio A, Munger KL (2016) Epidemiology of multiple scle-
rosis. From risk factor to prevention—an update. Semin Neurol 
36:103–114
 5. Bailey OT, Pappenheimer AM, Sargent F, Cheever MD, Daniels 
JB (1949) A murine virus (JHM) causing disseminated enceph-
alomyelitis with extensive destruction of myelin. II. Pathology. 
J Exp Med 90:195–212
 6. Baker D, Amor S (2012) Publication guidelines for referee-
ing and reporting on animal use in experimental autoimmune 
encephalomyelitis. J Neuroimmunol 242:78–83
 7. Baker D, O’Neill JK, Gschmeissner SE, Wilcox CE, Butter C, 
Turk JL (1990) Induction of chronic relapsing experimental 
allergic encephalomyelitis in Biozzi mice. J Neuroimmunol 
28:261–270
 8. Barnett MH, Prineas JW (2004) Relapsing and remitting multi-
ple sclerosis: pathology of the newly forming lesion. Ann Neu-
rol 55:458–468
 9. Bartholomäus I, Kawakami N, Odoardi F, Schläger C, Miljko-
vic D, Ellwart JW, Klinkert WE, Flügel-Koch C, Issekutz TB, 
Wekerle H, Flügel A (2009) Effector T cell interactions with 
meningeal vascular structures in nascent autoimmune CNS 
lesions. Nature 462:94–98
 10. Basso AS, Frenkel D, Quintana FJ, Costa-Pinto FA, Petrovic-
Stojkovic S, Puckett L, Monsonego A, Bar-Shir A, Engel Y, 
Gozin M, Weiner HL (2008) Reversal of axonal loss and disa-
bility in a mouse model of progressive multiple sclerosis. J Clin 
Invest 118:1532–1543
 11. Baxter AG, Hodgkin PD (2002) Activation rules: the two-signal 
theories of immune activation. Nat Rev Immunol 2:439–446
 12. Ben Nun A, Kaushnasky N, Kawakami N, Krishnamoorthy G, 
Berer K, Liblau R, Hohlfeld R, Wekerle H (2014) From classic 
to spontaneous and humanized models of multiple sclerosis: 
impact on understanding pathogenesis and drug development. J 
Autoimmun 54:33–50
 13. Ben-Nun A, Wekerle H, Cohen IR (1981) The rapid isolation of 
clonable antigen-specific T lymphocyte lines capable of mediat-
ing autoimmune encephalomyelitis. Eur J Immunol 11:195–199
 14. Bender SJ, Weiss SR (2010) Pathogenesis of murine coronavi-
rus in the central nervous system. J Neuroimmune Pharmacol 
5:336–354
 15. Berer K, Mues M, Koutrolos M, Rasbi ZA, Boziki M, Johner C, 
Wekerle H, Krishnamoorthy G (2011) Commensal microbiota 
and myelin autoantigen cooperate to trigger autoimmune demy-
elination. Nature 479:538–541
 16. Bernard CC (1976) Experimental autoimmune encephalomy-
elitis in mice: genetic control of susceptibility. J Immunogenet 
3:263–274
 17. Bettelli E, Pagany M, Weiner HL, Linington C, Sobel RA, 
Kuchroo VK (2003) Myelin oligodendrocyte glycoprotein-spe-
cific T cell receptor transgenic mice develop spontaneous auto-
immune optic neuritis. J Exp Med 197:1073–1081
 18. Bettelli E, Baeten D, Jäger A, Sobel RA, Kuchroo VK (2006) 
Myelin oligodendrocyte glycoprotein-specific T and B cells 
cooperate to induce a Devic-like disease in mice. J Clin Invest 
116:2393–2402
 19. Bieber AJ, Ure DR, Rodriguez M (2005) Genetically dominant 
spinal cord repair in a murine model of chronic progressive 
multiple sclerosis. J Neuropath Exp Neurol 64:46–57
 20. Billiau A, Matthys P (2001) Modes of action of Freund’s adju-
vants in experimental models of autoimmune diseases. J Leuko-
cyte Biol 70:849–860
 21. Blakemore WF (1982) Ethidium bromide induced demyeli-
nation in the spinal cord of the cat. Neuropath Appl Neurobiol 
8:365–375
 22. Blanc CA, Rosen H, Lane TE (2014) FTY720 (fingolimod) 
modulates the severity of viral-induced encephalomyelitis and 
demyelination. J Neuroinflammation 11:138
 23. Blauth K, Soltys J, Matschulat A, Reiter CR, Ritchie A, Baird 
NLO, Bennett JL, Owens GP (2015) Antibodies produced by 
clonally expanded plasma cells in multiple sclerosis cerebrospi-
nal fluid cause demyelination of spinal cord explants. Acta Neu-
ropathol 130:765–781
 24. Booss J, Esiri MM, Tourtellotte WW, Mason DY (1983) Immu-
nohistological analysis of T lymphocyte subsets in the central 
nervous system in chronic progressive multiple sclerosis. J Neu-
rol Sci 62:219–232
 25. Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, Reindl 
M, Adzemovic M, Bauer J, Berger T, Fujihara K, Itoyama Y, 
Lassmann H (2009) Neuromyelitis optica: pathogenicity of 
patient immunoglobulin in vivo. Ann Neurol 66:630–643
 26. Brosnan CF, Raine CS (2013) The astrocyte in multiple sclero-
sis revisited. Glia 61:453–465
 27. Cabarrocas J, Bauer J, Piaggio E, Liblau R, Lassmann H (2003) 
Effective and selective immune surveillance of the brain by 
MHC class I-restricted cytotoxic T lymphocytes. Eur J Immu-
nol 33:1174–1182
 28. Campbell GR, Ziabreva I, Reeve AK, Krishnan KJ, Reynolds R, 
Howell O, Lassmann H, Turnbull DM, Mahad DF (2010) Mito-
chondrial DNA deletions and neurodegeneration in multiple 
sclerosis. Ann Neurol 69:481–492
 29. Chen X, Winkler-Pickett RT, Carbonetti NH, Ortaldo RJ, 
Oppenheim HH, Howard OM (2006) Pertussis toxin as an adju-
vant suppresses the number and function of CD4+ CD25+ T 
regulatory cells. Eur J Immunol 36:671–680
 30. Crawford AH, Chambers C, Franklin RJ (2013) Remyelination: 
the true regeneration of the central nervous system. J Comp 
Pathol 149:242–254
241Acta Neuropathol (2017) 133:223–244 
1 3
 31. Crawford AH, Tripathi RB, Richardson WD, Franklin RJ (2016) 
Developmental origin of oligodendrocyte lineage cells deter-
mines response to demyelination and susceptibility to age-asso-
ciated functional decline. Cell Rep S2211–S47. doi:10.1016/j.
celrep.2016.03.069
 32. Cross AH, McCarron R, McFarlin DE, Raine CS (1987) Adop-
tively transferred acute and chronic relapsing autoimmune 
encephalomyelitis in the PL/J mouse and observations on altered 
pathology by intercurrent virus infection. Lab Invest 57:499–512
 33. Croxford JL, Ercolini AM, Degutes M, Miller SD (2006) Struc-
tural requirements for initiation of cross-reactivity and CNS 
autoimmunity with a PLP139-151 mimic peptide derived from 
murine hepatitis virus. Eur J Immunol 36:2671–2680
 34. Dandekar AA, Anghelina D, Perlman S (2004) Bystander CD8 
T-cell-mediated demyelination is interferon-gamma-depend-
ent in a coronavirus model of multiple sclerosis. Am J Pathol 
164:363–369
 35. Dandekar AA, Perlman S (2002) Virus induced demyelination 
in nude mice is mediated by gamma delta T cells. Am J Pathol 
161:1255–1263
 36. Dandekar AA, Wu GF, Pewe L, Perlman S (2001) Axonal dam-
age is T cell mediated and occurs concomitantly with demyeli-
nation in mice infected with a neurotropic coronavirus. J Virol 
75:6115–6120
 37. Denic A, Johnson AJ, Bieber AJ, Warrington AE, Rodriguez M, 
Pirko I (2011) The relevance of animal models in multiple scle-
rosis research. Pathophysiology 18:21–29
 38. Desai RA, Davies AL, Tachrount M, Kasti M, Laulund F, Golay 
X, Smith KJ (2016) Cause and prevention of demyelination in a 
model of multiple sclerosis. Ann Neurol 79:591–604
 39. Dörries R, Watanabe R, Wege H, ter Meulen V (1986) Murine 
coronavirus-induced encephalomyelitis in rats: analysis of 
immunoglobulins and virus-specific antibodies in serum and 
cerebrospinal fluid. J Neuroimmunol 12:131–142
 40. Doucette JR, Jiao R, Nazarali AJ (2010) Age-related and cupr-
izone-induced changes in myelin and transcription factor gene 
expression and in oligodendrocyte cell densities in the rostral 
corpus callosum of mice. Cell Mol Neurobiol 30:607–629
 41. Dumas A, Amiable N, de Rivero Vaccari JP, Chae JJ, Keane 
RW, Lacroix S, Vallieres L (2014) The inflammosome pyrin 
contributes to pertussis toxin-induced Il-1ß synthesis, neutro-
phil intravascular crawling and autoimmune encephalomyelitis. 
PLoS Pathog 10:1004150
 42. Ellmerich S, Takacs K, Mycko M, Waldner H, Wahid F, Boy-
ton RJ, Smith PA, Amor S, Baker D, Hafler DA, Kuchroo VK, 
Altmann DM (2004) Disease related epitope spread in a human-
ized T cell receptor transgenic model of multiple sclerosis. Eur 
J Immunol 34:1839–1848
 43. Felts PA, Woolston AM, Fernando HB, Asquith S, Gregson NA, 
Mizzi OJ, Smith KJ (2005) Inflammation and primary demy-
elination induced by the intraspinal injection of lipopolysaccha-
ride. Brain 128:1649–1666
 44. Ferguson B, Matyszak MK, Esiri MM, Perry VH (1997) Axonal 
damage in acute multiple sclerosis lesions. Brain 120:393–399
 45. Fischer MT, Wimmer I, Hoftberger R, Gerlach S, Haider L, 
Zrzavy T, Hametner S, Mahad D, Binder CJ, Krumbholz M, 
Bauer J, Bradl M, Lassmann H (2013) Disease-specific molecular 
events in cortical multiple sclerosis lesions. Brain 136:1799–1815
 46. Flügel A, Berkowicz T, Ritter T, Labeur M, Jenne DE, Li Z, Ell-
wart JW, Willem M, Lassmann H, Wekerle H (2001) Migratory 
activity and functional changes of green fluorescent effector 
cells before and during experimental autoimmune encephalo-
myelitis. Immunity 14:547–560
 47. Fog T (1950) Topographic distribution of plaques in the spi-
nal cord in multiple sclerosis. A.M.A. Arch Neurol Psychiat 
63:382–414
 48. Franklin RJ, Thao C, Sim FJ (2002) Ageing and CNS remyeli-
nation. NeuroReport 13:923–928
 49. Franklin RJM, ffrench-Constant C, Edgar J, Smith JM (2012) 
Neuroprotection and repair in multiple sclerosis. Nat Rev Neu-
rol 8:624–634
 50. Franklin RJM, Gallo V (2014) The translational biology of 
remyelination: past, present and future. Glia 62:1905–1915
 51. Friese MA, Jakobson KB, Friis L, Etzensperger R, Craner MJ, 
McMahon RM, Jensen LT, Huygelen V, Jones EY, Bell JI, Fug-
ger L (2008) Opposing effects of HLA class I molecules in tun-
ing autoreactive CD8+ T cells in multiple sclerosis. Nat Med 
14:1227–1235
 52. Frischer J, Weigand S, Guo Y, Kale N, Parisi J, Pirko I, Man-
drekar J, Bramow S, Metz I, Brück W, Lassmann H, Lucchinetti 
C (2015) Clinical and pathological insights into the dynamic 
nature of the white matter multiple sclerosis plaque. Ann Neu-
rol 78:710–721
 53. Frischer JM, Bramow S, Dal Bianco A, Lucchinetti CF, 
Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, 
Lassmann H (2009) The relation between inflammation 
and neurodegeneration in multiple sclerosis brains. Brain 
132:1175–1189
 54. Gardner C, Magliozzi R, Durrenberger PF, Howell OW, 
Rundle J, Reynolds T (2013) Cortical grey matter demylina-
tion can be induced by elevated pro-inflammatory cytokines 
in the subarachnoid space of MOG-immunized rats. Brain 
136:3596–3608
 55. Gilli F, Li L, Campbell SJ, Anthony DC, Pachner AR (2015) 
The effect of B-cell depletion in the Theiler’s model of multiple 
sclerosis. J Neurol Sci 359:40–47
 56. Gudi V, Gingele S, Skripuletz T, Stangel M (2014) Glial 
response during cuprizone-induced de- and remyelination in the 
CNS. Front Cell Neurosci 8:73
 57. Haider L, Zrzavy T, Hametner S, Höftberger R, Bagnato F, 
Grabner G, Trattnig S, Pfeifenbring S, Brück W, Lassmann H 
(2016) The topograpy of demyelination and neurodegeneration 
in the multiple sclerosis brain. Brain 139:807–815
 58. Hall SM (1972) The effect of injections of lysophosphatidyl 
choline into white matter of the adult mouse spinal cord. J Cell 
Sci 10:535–546
 59. Hametner S, Wimmer I, Haider L, Pfeifenbring S, Brück W, 
Lassmann H (2013) Iron and neurodegeneration in the multiple 
sclerosis brain. Ann Neurol 74:848–861
 60. Hampton DW, Serio A, Pryce G, Al-Izki S, Franklin JM, Gio-
vannoni G, Baker D, Chandran S (2013) Neurodegeneration 
progresses despite complete elimination of clinical relapses in 
a mouse model of multiple sclerosis. Acta Neuropath Commun 
1:84
 61. Hauser SL (2015) The Charcot lecture/beating MS: a story of B 
cells, with twists and turns. Mult Scler J 21:8–21
 62. Hayashi T, Morimoto C, Burks JS, Kerr C, Hauser SL (1988) 
Dual-label immunocytochemistry of the active multiple sclero-
sis lesion: major histocompatibility complex and activation anti-
gens. Ann Neurol 24:523–531
 63. Hiremath MM, Saito Y, Knapp GW, Ting JP, Suzuki K, Matsu-
shima GK (1998) Microglia/macrophage accumulation during 
cuprizone-induced demyelination in C57BL/6 mice. J Neuroim-
munol 92:38–49
 64. Höftberger R, Leisser M, Bauer J, Lassmann H (2015) Autoim-
mune encephalitis in humans: how closely does it reflect multi-
ple sclerosis? Acta Neuropathol Commun 3:80
 65. Homberger FR, Zhang L, Barthold SW (1998) Prevalence of 
enterotropic and polytropic mouse hepatitis virus in enzooti-
cally infected mouse colonies. Lab Anim Sci 48:50–54
 66. Houtman JJ, Fleming JO (1996) Pathogenesis of mouse hepati-
tis virus-induced demyelination. J Neurovirol 2:361–376
242 Acta Neuropathol (2017) 133:223–244
1 3
 67. Howe CL, Adelson JD, Rodriguez M (2007) Absence of per-
forin expression confers axonal protection despite demyelina-
tion. Neurobiol Dis 25:354–359
 68. Huizinga R, Heijmans N, Schubert P, Gschmeissner S, t Hart 
BA, Herrmann H, Amor S (2007) Immunization with neurofila-
ment light protein induces spastic paresis and axonal degenera-
tion in Biozzi ABH mice. J Neuropath Exp Neurol 66:295–304
 69. Huizinga R, Gerritsen W, Heijmans N, Amor S (2008) Axonal 
loss and gray matter pathology as a direct result of autoimmun-
ity to neurofilaments. Neurobiol Dis 32:461–470
 70. Huseby ES, Liggitt D, Brabb T, Schnabel B, Ohlen C, Gover-
man J (2001) A pathogenic role for myelin specific CD8(+) T 
cells in a model for multiple sclerosis. J Exp Med 194:669–676
 71. Ikota H, Iwasaki A, Kawarai M, Nakazato Y (2010) Neuromy-
elitis optica with intraspinal expansion of Schwann cell remy-
elination. Neuropathology 30:427–433
 72. International Multiple Sclerosis Genetics Consortium (2013) 
Analysis of immune-related loci identifies 48 new susceptibility 
variants for multiple sclerosis. Nat Genet 45:1353–1360
 73. Jagessar S, Heijmans N, Blezer E, Bauer J, Weissert R, ‘t Hart 
B (2015) Immune profile of an atypical EAE model in marmo-
set monkeys immunized with recombinant human myelin oli-
godendrocyte glycoprotein in incomplete Freund’s adjuvant. J 
Neuroinflamm 12:169
 74. Jeffery ND, Blakemoore WF (1995) Remyelination of mouse 
spinal cord axons demyelinated by local injection of lysoleci-
thin. J Neurocytol 24:775–781
 75. Kabat EA, Wolf A, Bezer AE, Murray JP (1951) Studies on 
acute disseminated encephalomyelitis produced experimentally 
in rhesus monkeys. J Exp Med 93:615–633
 76. Kamradt T, Soloway PD, Perkins DL, Gefter ML (1991) Pertus-
sis toxin prevents the induction of peripheral T cell anergy and 
enhances the T cell response to an encephalitogenic peptide of 
myelin basic protein. J Immunol 147:3296–3302
 77. Kawakami N, Nägerl UV, Odoardi F, Bonhoeffer T. Wekerle H, 
Flügel A (2005) Live imaging of effector cell trafficking and 
autoantigen recognition within unfolding autoimmune encepha-
lomyelitis lesions. J Exp Med 201:1805–1814
 78. Kim JH, Budde MD, Liang HF, Klein RS, Russell JH, Cross 
AH, Song SK (2006) Detecting axon damage in spinal cord 
from a mouse model of multiple sclerosis. Neurobiol Dis 
21:626–632
 79. Kim SM, Woodhall MR, Kim JS, Kim SJ, Park KS, Vincent A, 
Lee KW, Waters P (2015) Antibodies to MOG in adults with 
inflammatory demyelinating disease. Neurol Neuroimmunol 
Neuroinflamm 2:e163
 80. Kim TS, Perlman S (2005) Virus-specific antibody, in the 
absence of T cells, mediates demyelination in mice infected 
with a neurotropic coronavirus. Am J Path 166:801–810
 81. Kornek B, Storch MK, Weissert R, Wallstroem E, Stefferl A, 
Olsson T, Linington C, Schmidbauer M, Lassmann H (2000) 
Multiple sclerosis and chronic autoimmune encephalomyelitis: 
a comparative quantitative study of axonal injury in active, inac-
tive, and remyelinated lesions. Am J Pathol 157:267–276
 82. Kotter MR, Setzu A, Sim FJ, Van Rooijen N, Franklin RJ (2001) 
Macrophage depletion impairs oligodendrocyte remyelination 
following lysolecithin-induced demyelination. Glia 35:204–212
 83. Krishnamoorthy G, Lassmann H, Wekerle H, Holz A (2006) 
Spontaneous opticospinal encephalomyelitis in a double-trans-
genic mouse model of autoimmune T cell/B cell cooperation. J 
Clin Invest 116:2385–2392
 84. Krishnamoorthy G, Saxena A, Mars LT, Domingues HS, Men-
tele R, Ben-Nun A, Lassmann H, Dornmair K, Kurschus FC, 
Liblau RS, Wekerle H (2009) Myelin-specific T cells also rec-
ognize neuronal autoantigen in a transgenic mouse model of 
multiple sclerosis. Nat Med 15:626–632
 85. Kurosawa K, Misu T, Takai Y, Sato DK, Takahashi T, Abe Y, Iwa-
nari H, Ogawa R, Nakashima I, Fujihara K, Hamakubo T, Yasui 
M, Aoki M (2015) Severely exacerbated neuromyelitis optica rat 
model with extensive astrocytopathy by high affinity anti-aqua-
porin-4 monoclonal antibody. Acta Neuropathol Commun 3:82
 86. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Brück W, 
Rauschka H, Bergmann M, Schmidbauer M, Parisi JE, Lass-
mann H (2005) Cortical demyelination and diffuse white matter 
injury in multiple sclerosis. Brain 128:2705–2712
 87. Kutzelnigg A, Faber-Rod JC, Bauer J, Lucchinetti CF, 
Sorensen PS, Laursen H, Stadelmann C, Brück W, Rauschka 
H, Schmidbauer M, Lassmann H (2007) Widespread demy-
elination in the cerebellar cortex in multiple sclerosis. Brain 
Pathol 17:38–44
 88. Lampert PW, Sims JK, Kniazeff AJ (1973) Mechanisms of 
demyelination in JHM virus encephalomyelitis. Acta Neuro-
pathol 24:76–85
 89. Lassmann H, Wisniewski HM (1979) Chronic relapsing experi-
mental allergic encephalomyelitis: clinico-pathological compar-
ison with multiple sclerosis. Arch Neurol 36:490–497
 90. Lassmann H, Brunner C, Bradl M, Linington C (1988) Exper-
imental allergic encephalomyelitis: the balance between 
encephalitogenic T lymphocytes and demyelinating antibod-
ies determines size and structure of demyelinated lesions. Acta 
Neuropathol 75:566–576
 91. Lassmann H, Brück W, Lucchinetti C (2007) The immuno-
pathology of multiple sclerosis: an overview. Brain Pathol 
17:210–218
 92. Levine S (1960) Localization of allergic encephalomyelitis in 
lesions of cyanide encephalopathy. J Neuropath Exp Neurol 
19:238–247
 93. Levine S, Hoenig EM (1968) Induced localization of allergic 
adrenalitis and encephalomyelitis at sites of thermal injury. J 
Immunol 100:1310–1318
 94. Levy H, Assaf D, Frenkel D (2010) Characterization of brain 
lesions in a mouse model of progressive multiple sclerosis. Exp 
Neurol 226:148–158
 95. Levy Barazany H, Barazany D, Puckett L, Blanga-Kanfi S, 
Borenstein-Auerbach N, Yang K, Peron JP, Weiner HL, Frenkel 
D (2014) Brain MRI of nasal MOG therapeutic effect in relaps-
ing-progressive EAE. Exp Neurol 255:63–70
 96. Linington C, Bradl M, Lassmann H, Brunner C, Vass K (1988) 
Augmentation of demyelination in rat acute allergic encepha-
lomyelitis by circulating mouse monoclonal antibodies directed 
against a myelin/oligodendrocyte glycoprotein. Am J Pathol 
130:443–454
 97. Lipton HL, Twaddle G, Jelachich ML (1995) The predominant 
virus antigen burden is in macrophages in Theiler’s murine 
encephalomyelitis virus-induced demyelinating disease. J Virol 
69:2525–2533
 98. Lisak RP, Benjamins JA, Nedelkoska L, Barger JL, Ragheb 
S, Fan B, Ouamara N, Johnson TA, Rajasekharan S, Bar-Or A 
(2012) Secretory products of multiple sclerosis B-cells are cyto-
toxic to oligodendrocytes in vitro. J Neuroimmunol 246:85–95
 99. Lu C, Pelech S, Zhang H, Bond J, Spach K, Noubade R, Blan-
jenhorn EP, Teuscher C (2008) Pertussis toxin induces angio-
genesis in brain microvascular endothelial cells. J Neurosci Res 
86:2624–2640
 100. Lublin FD, Reingold SC (1996) Defining the clinical course of 
multiple sclerosis: results of an international survey. National 
Multiple Sclerosis Society (USA) Advisory Committee on 
Clinical Trials of New Agents in Multiple Sclerosis. Neurology 
46:907–911
 101. Lucchinetti CF, Popescu BF, Bunyan RF, Moll NM, Roemer SF, 
Lassmann H, Brück W, Parisi JE, Scheithauer BW, Giannini C, 
Weigand SD, Mandrekar J, Ransohoff RM (2011) Inflammatory 
243Acta Neuropathol (2017) 133:223–244 
1 3
cortical demyelination in early multiple sclerosis. N Engl J Med 
365:2188–2197
 102. Magliozzi R, Howell OW, Reeves C, Roncaroli F, Nicholas R, 
Serafini B, Aloisi F, Reynolds R (2010) A Gradient of neuronal 
loss and meningeal inflammation in multiple sclerosis. Ann 
Neurol 68:477–493
 103. Mahad DH, Trapp BD, Lassmann H (2015) Pathological 
mechanisms in progressive multiple sclerosis. Lancet Neurol 
14:183–193
 104. Mahad D, Ziabreva I, Lassmann H, Turnbull D (2008) Mito-
chondrial defects in acute multiple sclerosis lesions. Brain 
131:1722–1735
 105. Manrique-Hoyos N, Jürgens T, Gronborg M, Kreutzfeldt M, 
Schedensack M, Kuhlmann T, Schrick C, Brück W, Urlaub H, 
Simons M, Merkler D (2012) Late motor decline after accom-
plished remyelination: impact for progressive multiple sclero-
sis. Ann Neurol 71:227–244
 106. Marik C, Felts PA, Bauer J, Lassmann H, Smith KJ (2007) 
Lesion genesis in a subset of patients with multiple sclerosis: a 
role for innate immunity? Brain 130:2800–2815
 107. Mars LT, Bauer J, Gross DA, Bucciarelli F, Firat H, Hudrisier 
D, Lemonnier F, Kosmatopoulos K, Liblau RS (2007) CD8 T 
cell response to myelin oligodendrocyte glycoprotein-derived 
peptides in humanized HLA-A*0201-transgenic mice. J Immu-
nol 179:5090–5098
 108. Martinez NE, Karlsson F, Sato F, Kawai E, Omura S, Minagar 
A, Grisham MB, Tsunoda I (2014) Protective and detrimental 
roles for regulatory T cells in a viral model for multiple sclero-
sis. Brain Pathol 24:436–451
 109. Mathey EK, Derfuss T, Storch MK, Williams KR, Hales K, 
Woolley DR, Al-Hayani A, Davies SN, Rasband MN, Olsson 
T, Moldenhauer A, Velhin S, Hohlfeld R, Meinl E, Linington C 
(2007) Neurofascin as a novel target for autoantibody-mediated 
axonal injury. J Exp Med 204:2363–2372
 110. Matsushima GK, Morell P (2001) The neurotoxicant cuprizone, 
as a model to study demyelination and remyelination in the cen-
tral nervous system. Brain Pathol 11:107–116
 111. Mendel I, Kerlero de Rosbo N, Ben Nun A (1995) A myelin 
oligodendrocyte glycoprotein peptide induces typical chronic 
experimental autoimmune encephalomyelitis in H-2b mice: fine 
specificity and T cell receptor V beta expression of encephalito-
genic cells. Eur J Immunol 25:1951–1959
 112. Merkler D, Ernsting T, Kerschensteiner M, Brück W, Stadel-
mann C (2006) A new focal EAE model of cortical demy-
elination: multiple sclerosis-like lesions with rapid resolu-
tion of inflammation and extensive remyelination. Brain 
129:1972–1983
 113. Moll NM, Rietsch AM, Ransohoff AJ, Cossoy MB, Huang D, 
Eichler FS, Trapp BD, Ransohoff RM (2008) Cortical demyeli-
nation in PML and MS: similarities and differences. Neurology 
70:336–343
 114. Monteyne P, Bureau JF, Brahic M (1997) The infection of 
mouse by Theiler’s virus: from genetics to immunology. Immu-
nol Rev 159:163–176
 115. Mues M, Bartholomäus I, Thestrup T, Griesbeck O, Wekerle 
H, Kawakami N, Krishnamoorthy G (2013) Real-time in vivo 
analysis of T cell activation in the central nervous system using 
genetically encoded calcium indicator. Nat Med 19:778–783
 116. Na SY, Cao Y, Toben C, Nitschke L, Stadelmann C, Gold R, 
Schimpl A, Hünig T (2008) Naive CD8 T-cells initiate sponta-
neous autoimmunity to a sequestered model antigen of the cen-
tral nervous system. Brain 131:2353–2365
 117. Na SY, Hermann A, Sanchez-Ruiz M, Storch A, Deckert M, 
Hünig T (2012) Oligodendrocytes enforce immune tolerance 
of the uninfected brain by purging the peripheral repertoire of 
autoreactive CD8+ T cells. Immunity 37:134–146
 118. Nikic I, Merkler D, Sorbara C, Brinkoetter M, Kreutzfeldt M, 
Bareyre FM, Brück W, Bishop D, Misgeld T, Kerschensteiner 
M (2011) A reversible form of axon damage in experimental 
autoimmune encephalomyelitis and multiple sclerosis. Nat Med 
17:495–499
 119. Njenga MK, Coenen MJ, DeCuir N, Yeh HY, Rodriguez M 
(2000) Short term treatment with interferon-alpha/beta pro-
motes remyelination, whereas long term treatment aggravates 
demyelination in a murine model of multiple sclerosis. J Neuro-
sci Res 59:661–670
 120. Nexo BA, Jensen SB, Nissen KK, Hansen B, Laska MJ (2016) 
Two endogenous retroviral loci appear to contribute to multiple 
sclerosis. BMC Neurol 16:57
 121. Olson JK, Eagar TN, Miller SD (2002) Functional activation of 
myelin-specific T cells by virus-induced molecular mimicry. J 
Immunol 169:2719–2726
 122. Pachner AR, Li L, Lagunoff D (2011) Plasma cells in the cen-
tral nervous system in the Theiler’s virus model of multiple 
sclerosis. J Neuroimmunol 232:35–40
 123. Paterson PY (1960) Transfer of allergic encephalomyelitis in 
rats by means of lymph node cells. J Exp Med 111:119–135
 124. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordi-
nates, 4th edn. Academic, San Diego
 125. Peferoen LAN, Breur M, van de Berg S, Peferoen-Baert R, 
Boddeke EHWGM, van der Valk P, Pryce G, van Noort JM, 
Baker D, Amor S (2016) Ageing and recurrent episodes of 
neuroinflammation promote progressive EAE in Biozzi mice. 
Immunology 149:146–156
 126. Peters A, Pitcher LA, Sullivan JM, Mitsdoerffer M, Acton SE, 
Franz B, Wucherpfennig K, Turley S, Carroll MC, Sobel RA, 
Bettelli E, Kuchroo VK (2011) Th17 cells induce ectopic lym-
phoid follicles in central nervous system tissue inflammation. 
Immunity 35:986–996
 127. Pierson E, Simmons SB, Castelli L, Goverman JM (2012) 
Mechanisms regulating regional localization of inflammation 
during CNS autoimmunity. Immunol Rev 248:205–215
 128. Pirko I, Johnson AJ (2008) Neuroimaging of demyelina-
tion and remyelination models. Curr Top Microbiol Immunol 
318:241–266
 129. Pohl M, Kawakami N, Kitic M, Bauer J, Martins R, Fischer 
MT, Machado-Santos J, Mader S, Ellwart JW, Misu T, Fujihara 
K, Wekerle H, Reindl M, Lassmann H, Bradl M (2013) T cell-
activation in neuromyelitis optica lesions plays a role in their 
formation. Acta Neuropathol Commun 1:85
 130. Pöllinger B, Krishnamoorthy G, Berer K, Lassmann H, Bösl 
MR, Dunn R, Domingues HS, Holz A, Kurschus FC, Wekerle 
H (2009) Spontaneous relapsing-remitting EAE in the SJL/J 
mouse: MOG reactive transgenic T cells recruit endogeneous 
MOG-specific B cells. J Exp Med 206:1303–1316
 131. Pomeroy IM, Matthews PM, Frank JA, Jordan EK, Esiri MM 
(2005) Demyelinated neocortical lesions in marmoset autoim-
mune encephalomyelitis mimic those in multiple sclerosis. 
Brain 128:2713–2721
 132. Praet J, Guglielmetti C, Berneman Z, Van der Linden A, Pon-
saerts P (2014) Cellular and molecular neuropathology of the 
cuprizone mouse model: clinical relevance for multiple sclero-
sis. Neurosci Behav Rev 47:485–505
 133. Reboldi A, Coisne C, Baumjohann D, Benvenuto F, Bottinelli 
D, Lira S, Uccelli A, Lanzavecchia A, Engelhardt B, Sallusto 
F (2009) C-C chemokine receptor-6 regulated entry of TH-17 
cells into the CNS through the choroid plexus is required for the 
induction of EAE. Nat Immunol 10:514–523
 134. Rivera-Quinones C, McGavern D, Schmelzer JD, Hunter SF, 
Low PA, Rodriguez M (1998) Absence of neurological deficits 
following extensive demyelination in a class I-deficient murine 
model of multiple sclerosis. Nat Med 4:187–193
244 Acta Neuropathol (2017) 133:223–244
1 3
 135. Rivers TM, Sprunt DH, Berry GP (1933) Observations on 
attempts to produce acute disseminated encephalomyelitis in 
monkeys. J Exp Med 58:39–53
 136. Rodriguez M, Leibowitz JL, Lampert PW (1983) Persis-
tent infection of oligodendrocytes in Theiler’s virus-induced 
encephalomyelitis. Ann Neurol 13:426–433
 137. Rodriguez M, Oleszak E, Leibowitz J (1987) Theiler’s murine 
encephalomyelitis: a model of demyelination and persistence of 
virus. Crit Rev Immunol 7:325–365
 138. Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papa-
dopoulos MC (2010) Intra-cerebral injection of neuromyelitis 
optica immunoglobulin G and human complement produces 
neuromyelitis optica lesions in mice. Brain 133:349–361
 139. Saadoun S, Waters P, Owens GP, Bennett JL, Vincent A, Papado-
poulos MC (2014) Neuromyelitis optica MOG-IgG causes revers-
ible lesions in the mouse brain. Acta Neuropath Commun 2:35
 140. Saxena A, Bauer J, Scheikl T, Zappulla J, Audebert M, Desbois 
S, Waisman A, Lassmann H, Liblau RS, Mars LT (2008) Cut-
ting edge: multiple sclerosis-like lesions induced by effector 
CD8 T cells recognizing a sequestered antigen on oligodendro-
cytes. J Immunol 181:1617–1621
 141. Scalfari A, Neuhaus A, Daumer M, Ebers GC, Muraro PA 
(2011) Age and disability accumulation in multiple sclerosis. 
Neurology 77:1246–1252
 142. Scheikl T, Pugnolet B, Dalard C, Desbois S, Raison D, Yamazaki 
M, Saoudi A, Bauer J, Lassmann H, Hardin-Bouzet H, Liblau 
RS (2012) Cutting edge: neuronal recognition by CD8 T cells 
elicits central diabetes insipidus. J Immunol 188:4731–4735
 143. Scheld M, Rüther BJ, Große-Veldmann R, Ohl K, Tenbrock K, 
Dreymüller D, Fallier-Becker P, Zendedel A, Beyer C, Clarner T, 
Kipp M (2016) Neurodegeneration triggers peripheral immune 
cell recruitment into the forebrain. J Neurosci 36:1410–1415
 144. Schuh C, Wimmer I, Hametner S, Haider L, Van Dam AM, 
Liblau RS, Smith KJ, Probert L, Binder CJ, Bauer J, Bradl M, 
Mahad D, Lassmann H (2014) Oxidative injury in multiple 
scerosis is only partly reflected in experimental disease models. 
Acta Neuropathol 128:247–266
 145. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fide-
lus-Gort R, Kasper LH (2008) Repeated subcutaneous injec-
tions of IL12/23 p40 neutralising antibody, ustekinumab, in 
patients with relapsing-remitting multiple sclerosis: a phase II, 
double-blind, placebo-controlled, randomised, dose-ranging 
study”. Lancet Neurol 7:796–804
 146. Seitelberger F, Jellinger K, Tschabitscher H (1958) Zur Gen-
ese der akuten Entmarkungsencephalitis. Wien Klein Wschr 
70:453–459
 147. Sepulveda M, Amangue T, Martinez-Hernandez E, Arrambide 
G, Sola-Valls N, Sabater L, Tellez N, Midaglia L, Arino H, 
Peschl P, Reindl M, Rovira A, Montalban X, Blanco Y, Dalmau 
J, Graus F, Saiz A (2016) Clinical spectrum associated with 
MOG autoimmunity in adults: significance of sharing rodent 
MOG epitopes. J Neurol 263:1349–1360
 148. Sharma R, Fischer MT, Bauer J, Felts PA, Smith KJ, Misu T, 
Fujihara K, Bradl M, Lassmann H (2010) Inflammation induced 
by innate immunity in the central nervous system leads to pri-
mary astrocyte dysfunction followed by demyelination. Acta 
Neuropathol 120:223–236
 149. Shen S, Sandoval J, Swiss VA, Li J, Dupree J, Franklin RJ, 
Casacchia-Bonnefil P (2008) Age-dependent epigenetic control 
of differentiation inhibitors is critical for remyelination effi-
ciency. Nat Neurosci 11:1024–1034
 150. Singer BA (2016) Parental treatment of multiple sclerosis: the 
advent of monoclonal antbodies. Semin Neurol 36:140–147
 151. Soulika AM, Lee E, McCauley E, Miers L, Bannerman P, Pleasure 
D (2009) Initiation and progression of axonopathy in experimental 
autoimmune encephalomyelitis. J Neurosci 29:14965–14979
 152. Steinman L, Zamvill SS (2016) Beginning of the end of two-
stage theory purporting inflammation then degeneration 
explains pathogenesis of progressive multiple sclerosis. Curr 
Opin Neurol 29:340–344
 153. Stohlman SA, Hinton DR (2001) Viral induced demyelination. 
Brain Pathol 11:92–106
 154. Stohlman SA, Weiner LP (1981) Chronic central nervous sys-
tem demyelination in mice after JHM virus infection. Neurol-
ogy 31:38–44
 155. Storch MK, Bauer J, Linington C, Olsson T, Weissert R, Lass-
mann H (2006) Cortical demyelination can be modeled in spe-
cific rat models of autoimmune encephalomyelitis and is major 
histocompatability complex (MHC) haplotype-related. J Neuro-
pathol Exp Neurol 65:1137–1142
 156. Storch MK, Stefferl A, Brehm U, Weissert R, Wallström E, 
Kerschensteiner M, Olsson T, Linington C, Lassmann H (1998) 
Autoimmunity to myelin oligodendrocyte glycoprotein in rats 
mimics the spectrum of multiple sclerosis pathology. Brain 
Pathol 8:681–694
 157. Stuart G, Krikorian KS (1928) The neuro-paralytic accidents of 
anti-rabies treatment. Ann Trop Med Parasitol 22:327–377
 158. Sun D, Whitaker JN, Huang Z, Liu D, Coleclough C, Wekerle 
H, Raine CS (2001) Myelin antigen-specific CD8+ T cells are 
encephalitogenic and produce severe disease in C57BL/6 mice. 
J Immunol 166:7579–7587
 159. Tabira T, Itoyama I, Kuroiwa Y (1984) The role of locally 
retained antigens in chronic relapsing experimental allergic 
encephalomyelitis in guinea pigs. Prog Clin Biol Res 146:43–48
 160. Uchimura I, Shiraki H (1957) A contribution to the classifica-
tion and the pathogenesis of demyelinating encephalomyelitis. J 
Neuropathol Exp Neurol 16:139–203
 161. Van Oosten BW, Lai M, Hodgkinson S, Barkhof F, Miller DH, 
Moseley IF, Thompson AJ, Rudge P, Mc Dougall A, McLeod 
JG, Ader HJ, Polman CH (1997) Treatment of multiple sclerosis 
with the monoclonal anti-CD4 antibody cM-T412: results of a 
randomized, double blind, placebo-controlled MR-monitored 
phase II trial. Neurology 49:351–357
 162. Vass K, Heininger K, Schäfer B, Linington C, Lassmann H 
(1992) Interferon-gamma potentiates antibody mediated demy-
elination in vivo. Ann Neurol 32:198–206
 163. Vogel DY, Vereyken EJ, Glim JE, Heijnen PD, Moeton M, van 
der Valk P, Amor S, Teunissen CE, van Horssen J, Dijkstra CD 
(2013) Macrophages in inflammatory multiple sclerosis lesions 
have an intermediate activation status. J Neuroinflamm 10:35
 164. Watanabe R, Wege H, ter Meulen V (1983) Adoptive transfer of 
EAE-like lesions from rats with coronavirus-induced demyeli-
nating encephalomyelitis. Nature 305:150–153
 165. Weissert R, Wallström E, Storch MK, Stefferl A, Lorentzen J, 
Lassmann H, Linington C, Olsson T (1998) MHC haplotype 
dependent regulation of MOG-induced EAE in rats. J Clin 
Invest 102:1265–1273
 166. Wekerle H, Kojima K, Lannes Vieira J, Lassmann H, Linington 
C (1994) Animal models. Ann Neurol Suppl S47–S53
 167. Wekerle H, Linington C, Lassmann H, Meyermann R (1986) 
Cellular immune reactivity within the CNS. Trends Neurosci 
9:271–277
 168. Wu GF, Perlman S (1999) Macrophage infiltration, but not 
apoptosis, is correlated with immune-mediated demyelination 
following murine infection with a neurotropic coronavirus. J 
Virol 73:8771–8780
 169. Zeka B, Hastermann M, Hochmeister S, Kögl N, Kaufmann N, 
Schanda K, Mader S, Misu T, Rommer P, Fujihara K, Illes Z, 
Leutmezer F, Sato DK, Nakashima I, Reindl M, Lassmann H, 
Bradl M (2015) Highly encephalitogenic aquaporin 4-specific 
T cells and NMO-IgG jointly orchestrate lesion location and tis-
sue damage in the CNS. Acta Neuropathol 130:783–798
